Zydus gets USFDA nod to market cancer treatment generic injection
–>
.sticky .site-header__logo img{width:166px;height:30px;margin-top: -6px;} @media only screen and (max-width: 767px){ .site-header__logo img{width:180px;height:33px;margin-top:3px;} .sticky .site-header__logo img{width:180px;height:33px;margin-top:3px;} }
New Delhi:
![\"\"](\/\/health.economictimes.indiatimes.com\/Themes\/Release\/images\/responsive\/ethealthworld-default.jpg\")
The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.
The drug will be manufactured at the group’s injectable manufacturing facility at Ahmedabad, it added.As per IQVIA MAT May 2023 data, Plerixafor injection single-dose vials had annual sales of USD 210 million in the US.Shares of Zydus were trading 4.39 per cent up at Rs 649.80 apiece on the BSE.","next_sibling":[{"msid":102134836,"title":"Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options","entity_type":"ARTICLE","link":"\/news\/pharma\/research-development\/illumina-and-pillar-biosciences-partner-to-improve-access-to-personalized-cancer-treatment-options\/102134836","category_name":null,"category_name_seo":"pharma\/research-development"}],"related_content":[],"msid":102172055,"entity_type":"ARTICLE","title":"Zydus gets USFDA nod to market cancer treatment generic injection","synopsis":"\u200b\u200b The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.","titleseo":"pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection","status":"ACTIVE","authors":[],"Alttitle":{"minfo":""},"artag":"PTI","artdate":"2023-07-27 16:31:20","lastupd":"2023-07-27 16:35:24","breadcrumbTags":["usfda","zydus lifesciences","zydus","cancer","healthnews"],"secinfo":{"seolocation":"pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection"}}” data-authors=”[” data-category-name data-category_id data-date=”2023-07-27″ data-index=”article_1″ readability=”2.6437399247716″>
The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.
New Delhi:
![](https://health.economictimes.indiatimes.com/Themes/Release/images/responsive/ethealthworld-default.jpg)
Zydus Lifesciences on Thursday said it has received approval from the US health regulator to market a cancer treatment generic injection in the American market.
The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.
The drug will be manufactured at the group’s injectable manufacturing facility at Ahmedabad, it added.As per IQVIA MAT May 2023 data, Plerixafor injection single-dose vials had annual sales of USD 210 million in the US.Shares of Zydus were trading 4.39 per cent up at Rs 649.80 apiece on the BSE.
<span id="etb2b-news-detail-page" class="etb2b-module-ETB2BNewsDetailPage" data-news-id="102172055" data-news="{"link":"\/news\/pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection\/102172055","seolocation":"\/news\/pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection\/102172055","seolocationalt":"\/news\/pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection\/102172055","seometatitle":false,"seo_meta_description":"\u200b\u200b The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.","canonical_url":false,"url_seo":"\/news\/pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection\/102172055","category_name":"Research & Development","category_link":"\/news\/pharma\/research-development","category_name_seo":"pharma\/research-development","updated_at":"2023-07-27 16:35:24","artexpdate":"2043-07-27 15:20:52","agency_name":"PTI","agency_link":"\/agency\/87654375\/PTI","read_duration":"1 min","keywords":[{"id":44669,"name":"usfda","type":"General","weightage":100,"keywordseo":"usfda","botkeyword":false,"source":"Orion","link":"\/tag\/usfda"},{"id":13247465,"name":"zydus lifesciences","type":"General","weightage":80,"keywordseo":"zydus-lifesciences","botkeyword":false,"source":"Orion","link":"\/tag\/zydus+lifesciences"},{"id":6559680,"name":"zydus","type":"General","weightage":80,"keywordseo":"zydus","botkeyword":false,"source":"Orion","link":"\/tag\/zydus"},{"id":6355291,"name":"cancer","type":"General","weightage":20,"keywordseo":"cancer","botkeyword":false,"source":"Orion","link":"\/tag\/cancer"},{"id":9731207,"name":"healthnews","type":"General","weightage":20,"keywordseo":"healthnews","botkeyword":false,"source":"Orion","link":"\/tag\/healthnews"}],"read_industry_leader_count":false,"read_industry_leaders":false,"embeds":[{"title":"Zydus gets USFDA nod to market cancer treatment generic injection","type":"image","caption":false,"elements":[]}],"thumb_big":"https:\/\/etimg.etb2bimg.com\/thumb\/msid-102172055,imgsize-15182,width-1200,height=765,overlay-ethealth\/pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection.jpg","thumb_small":"https:\/\/etimg.etb2bimg.com\/thumb\/img-size-15182\/102172055.cms?width=150&height=112","time":"2023-07-27 16:31:20","is_live":false,"prime_id":0,"highlights":[],"highlights_html":"","also_read_available":false,"body":"
New Delhi:
![\"\"](\/\/health.economictimes.indiatimes.com\/Themes\/Release\/images\/responsive\/ethealthworld-default.jpg\")
The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.
The drug will be manufactured at the group’s injectable manufacturing facility at Ahmedabad, it added.As per IQVIA MAT May 2023 data, Plerixafor injection single-dose vials had annual sales of USD 210 million in the US.Shares of Zydus were trading 4.39 per cent up at Rs 649.80 apiece on the BSE.","next_sibling":[{"msid":102134836,"title":"Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options","entity_type":"ARTICLE","link":"\/news\/pharma\/research-development\/illumina-and-pillar-biosciences-partner-to-improve-access-to-personalized-cancer-treatment-options\/102134836","category_name":null,"category_name_seo":"pharma\/research-development"}],"related_content":[],"msid":102172055,"entity_type":"ARTICLE","title":"Zydus gets USFDA nod to market cancer treatment generic injection","synopsis":"\u200b\u200b The company has received final approval from the USFDA for Plerixafor injection, which is used by patients with certain types of cancer to prepare them for stem cell transplant, Zydus Lifesciences said in a statement.","titleseo":"pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection","status":"ACTIVE","authors":[],"Alttitle":{"minfo":""},"artag":"PTI","artdate":"2023-07-27 16:31:20","lastupd":"2023-07-27 16:35:24","breadcrumbTags":["usfda","zydus lifesciences","zydus","cancer","healthnews"],"secinfo":{"seolocation":"pharma\/research-development\/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection"}}” data-news_link=”https://health.economictimes.indiatimes.com/news/pharma/research-development/zydus-gets-usfda-nod-to-market-cancer-treatment-generic-injection/102172055″>
–>
<!– –>
Source – ETHealth World
All Comments
<!–
–> <!–
–>
Find this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions
REASONS FOR REPORTING